Cargando…
Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival
Systematic treatment of advanced non-small cell lung cancer (NSCLC) includes targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The development of skin rash and its intensity have been associated with EGFR TKI’s efficacy. The main purpose of this study...
Autores principales: | Kainis, Ilias, Syrigos, Nikolaos, Kopitopoulou, Alexandra, Gkiozos, Ioannis, Filiou, Effrosyni, Nikolaou, Vasiliki, Papadavid, Evangelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844560/ https://www.ncbi.nlm.nih.gov/pubmed/28390118 http://dx.doi.org/10.3727/096504017X14913452320194 |
Ejemplares similares
-
Clinical and Surgical-Pathological Staging in Early Non-Small Cell Lung Cancer
por: Koukis, Ioannis, et al.
Publicado: (2013) -
Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013) -
Sampling Versus Systematic Full Lymphatic Dissection in Surgical Treatment of Non-Small Cell Lung Cancer
por: Koulaxouzidis, Georgios, et al.
Publicado: (2013) -
Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
por: Kast, R. E.
Publicado: (2015) -
High-dose bevacizumab for radiation-induced brain necrosis: a case report
por: Panagiotou, Emmanouil, et al.
Publicado: (2023)